Cargando…

Synthesis and Preclinical Evaluation of [Methylpiperazine-(11)C]brigatinib as a PET Tracer Targeting Both Mutated Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase

[Image: see text] Brigatinib, a tyrosine kinase inhibitor (TKI) with specificity for gene rearranged anaplastic lymphoma kinase (ALK), such as the EML4–ALK, has shown a potential to inhibit mutated epidermal growth factor receptor (EGFR). In this study, N-desmethyl brigatinib was successfully synthe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Högnäsbacka, Antonia A., Poot, Alex J., Kooijman, Esther, Schuit, Robert C., Schreurs, Maxime, Verlaan, Mariska, Beaino, Wissam, van Dongen, Guus A. M. S., Vugts, Danielle J., Windhorst, Albert D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2023
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510377/ https://www.ncbi.nlm.nih.gov/pubmed/37647220 http://dx.doi.org/10.1021/acs.jmedchem.3c00722

Ejemplares similares

The Development of Positron Emission Tomography Tracers for In Vivo Targeting the Kinase Domain of the Epidermal Growth Factor Receptor
por: Högnäsbacka, Antonia, et al.
Publicado: (2022)

Synthesis and Preclinical Evaluation of the First Carbon-11 Labeled PET Tracers Targeting Substance P(1–7)
por: Pekošak, Aleksandra, et al.
Publicado: (2018)

Performance of nanoScan PET/CT and PET/MR for quantitative imaging of (18)F and (89)Zr as compared with ex vivo biodistribution in tumor-bearing mice
por: Chomet, Marion, et al.
Publicado: (2021)

Novel Thienopyrimidine-Based PET Tracers for P2Y(12) Receptor Imaging in the Brain
por: van der Wildt, Berend, et al.
Publicado: (2021)

Correction to Novel Thienopyrimidine-Based PET Tracers for P2Y(12) Receptor Imaging in the Brain
por: van der Wildt, Berend, et al.
Publicado: (2022)

Advancing (89)Zr-immuno-PET in neuroscience with a bispecific anti-amyloid-beta monoclonal antibody - The choice of chelator is essential
por: Wuensche, Thomas E., et al.
Publicado: (2022)

Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical (89)Zr-immuno-PET
por: Chomet, Marion, et al.
Publicado: (2020)

Pretargeted PET Imaging with a TCO-Conjugated Anti-CD44v6 Chimeric mAb U36 and [(89)Zr]Zr-DFO-PEG(5)-Tz
por: Lumen, Dave, et al.
Publicado: (2022)

Immuno-PET Imaging of Atherosclerotic Plaques with [(89)Zr]Zr-Anti-CD40 mAb—Proof of Concept
por: Poels, Kikkie, et al.
Publicado: (2022)

In vivo evaluation of two tissue transglutaminase PET tracers in an orthotopic tumour xenograft model
por: van der Wildt, Berend, et al.
Publicado: (2018)

Application of (89)Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-ß monoclonal antibody
por: Stergiou, N., et al.
Publicado: (2023)

PET imaging of P2X(7)R in the experimental autoimmune encephalomyelitis model of multiple sclerosis using [(11)C]SMW139
por: Beaino, Wissam, et al.
Publicado: (2020)

Towards PET imaging of the dynamic phenotypes of microglia
por: Beaino, Wissam, et al.
Publicado: (2021)

Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor
por: Gupta, Neeraj, et al.
Publicado: (2023)

The P2X(7) receptor tracer [(11)C]SMW139 as an in vivo marker of neuroinflammation in multiple sclerosis: a first-in man study
por: Hagens, Marloes H. J., et al.
Publicado: (2019)

Identification of the allosteric P2X(7) receptor antagonist [(11)C]SMW139 as a PET tracer of microglial activation
por: Janssen, Bieneke, et al.
Publicado: (2018)

PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET
por: van Dongen, Guus A. M. S., et al.
Publicado: (2012)

State of the Art in Radiolabeling of Antibodies with Common and Uncommon Radiometals for Preclinical and Clinical Immuno-PET
por: Chomet, Marion, et al.
Publicado: (2021)

Imaging the TGFβ type I receptor in pulmonary arterial hypertension
por: Rotteveel, Lonneke, et al.
Publicado: (2023)

State of the art procedures towards reactive [(18)F]fluoride in PET tracer synthesis
por: Haveman, Lizeth Y. F., et al.
Publicado: (2023)

α‐Synuclein Radiotracer Development and In Vivo Imaging: Recent Advancements and New Perspectives
por: Alzghool, Obada M., et al.
Publicado: (2022)

Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice
por: Siaw, Joachim T., et al.
Publicado: (2016)

The Effect of a High‐Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers
por: Tugnait, Meera, et al.
Publicado: (2018)

Development of [(11)C]vemurafenib employing a carbon-11 carbonylative Stille coupling and preliminary evaluation in mice bearing melanoma tumor xenografts
por: Slobbe, Paul, et al.
Publicado: (2017)

Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib
por: Rijavec, Erika, et al.
Publicado: (2022)

Pharmacometric analyses and clinical evidence for brigatinib dosing in anaplastic lymphoma kinase‐positive non‐small cell lung cancer
por: Gupta, Neeraj, et al.
Publicado: (2022)

P1166: BRIGATINIB IN PATIENTS WITH ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA WHO HAVE FAILED BRENTUXIMAB VEDOTIN
por: Veleanu, Layla, et al.
Publicado: (2023)

(±)-2-Methylpiperazin-1-ium perchlorate
por: Peng, Cong-Hu
Publicado: (2010)

1-Methylpiperazine-1,4-diium dipicrate
por: Dutkiewicz, Grzegorz, et al.
Publicado: (2011)

Brigatinib for non-small cell lung cancer
Publicado: (2020)

Investigation into the Formation of Impurities during the Optimization of Brigatinib
por: Guo, Aofeng, et al.
Publicado: (2020)

Effect of severe renal impairment on the pharmacokinetics of brigatinib
por: Gupta, Neeraj, et al.
Publicado: (2021)

Brigatinib pharmacokinetics in patients with chronic hepatic impairment
por: Hanley, Michael J., et al.
Publicado: (2023)

Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase–Positive Non‐Small Cell Lung Cancer: Exposure–Response Analyses of Pivotal ALTA Study
por: Gupta, Neeraj, et al.
Publicado: (2020)

Synthesis and preliminary preclinical evaluation of fluorine-18 labelled isatin-4-(4-methoxyphenyl)-3-thiosemicarbazone ([(18)F]4FIMPTC) as a novel PET tracer of P-glycoprotein expression
por: Verbeek, Joost, et al.
Publicado: (2018)

Corrigendum to: Brigatinib dose rationale in anaplastic lymphoma kinase–positive non‐small cell lung cancer: Exposure–response analyses of pivotal ALTA study
Publicado: (2021)

Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China
por: Luo, Xia, et al.
Publicado: (2022)

4-Benzyl-N-methylpiperazine-1-carbothioamide
por: Alanazi, Amer M., et al.
Publicado: (2012)

Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer
por: Gupta, Neeraj, et al.
Publicado: (2020)

Simultaneous Quantification of Brigatinib and Brigatinib-Analog in Rat Plasma and Brain Homogenate by LC-MS/MS: Application to Comparative Pharmacokinetic and Brain Distribution Studies
por: Li, Bo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_cjd4ln6g2jqt52viuc0rkg8ng4